Evaluate Safety, Tolerability and Pharmacokinetics of HLX22 in Patients With Advanced Solid Tumors Overexpressing HER2
Last updated on July 2021Recruitment
- Recruitment Status
- Active, not recruiting
- Estimated Enrollment
- 30
Summary
- Conditions
- Solid Tumor
- Type
- Interventional
- Phase
- Phase 1
- Design
- Allocation: N/AIntervention Model: Single Group AssignmentMasking: None (Open Label)Primary Purpose: Treatment
Participation Requirements
- Age
- Between 18 years and 75 years
- Gender
- Both males and females
Description
This study is an open-label and dose escalation study aimed at exploring the safety and MTD of HLX22. Four dose levels are designed for HLX22 in this study: 1, 3, 10, and 25 mg/kg/3 weeks. The 3 mg/kg/3 weeks will serve as the starting dose. The study will use a BOIN design to assign doses to the pa...
This study is an open-label and dose escalation study aimed at exploring the safety and MTD of HLX22. Four dose levels are designed for HLX22 in this study: 1, 3, 10, and 25 mg/kg/3 weeks. The 3 mg/kg/3 weeks will serve as the starting dose. The study will use a BOIN design to assign doses to the patients, and thereby determine the MTD of HLX22.
Tracking Information
- NCT #
- NCT03916094
- Collaborators
- Not Provided
- Investigators
- Principal Investigator: Yanhua Ding The First Hospital of Jilin University
Get Well Soon